Literature DB >> 15635165

Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits.

Masahiro Orihashi1, Yuichiro Shima, Hiroshi Tsuneki, Ikuko Kimura.   

Abstract

The present study was performed to evaluate the intraocular pressure (IOP)-lowering effect of nipradilol in combination with latanoprost on ocular normotensive and hypertensive rabbits. IOP was measured using an applanation pneumatonograph under topical application of 0.4% oxybuprocaine hydrochloride for corneal anesthesia. Ocular hypertension was induced by injection of 0.1 ml hypertonic saline (5% NaCl) into the vitreous body. Saline, nipradilol, latanoprost, sodium nitroprusside (SNP) or indomethacin was then instilled just after 5% NaCl injection. All drugs were instilled in the inferior conjunctival sac, using 50 microl drops. If more than two drugs were used, they were applied 5 min apart. Nipradilol lowered IOP in both ocular normotensive rabbits and ocular hypertensive rabbits, whereas latanoprost did not lower IOP in either. When nipradilol was applied in combination with latanoprost, the reduction in ocular hypertension was significantly enhanced, compared to the effect of nipradilol alone. A significantly potent reduction in ocular hypertension was also observed by the SNP-latanoprost combination. The IOP-lowering effects of SNP in combination with latanoprost were abolished by treatment with indomethacin. These results indicate that the IOP-lowering effect of latanoprost was enhanced when applied in combination with nipradilol or SNP, both of which have nitric oxide (NO)-donating actions. Since both combined effects were abolished by treatment with indomethacin, the mechanisms by which nipradilol combined with latanoprost lowered ocular hypertension may be related, at least in part, to the production of prostaglandins via the NO-donating action of nipradilol.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15635165     DOI: 10.1248/bpb.28.65

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  13 in total

1.  In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.

Authors:  Tamara Martínez; Maria Victoria González; Ingo Roehl; Natalia Wright; Covadonga Pañeda; Ana Isabel Jiménez
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

2.  Consequences of Puberty on Efficacy of Intraocular Pressure-Lowering Drugs in Male Dutch-Belted Rabbits.

Authors:  Cassandra L Hays; Kingsley C Okafor; Shan Fan; Robin High; Dhirendra P Singh; Carol B Toris
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-18       Impact factor: 2.671

3.  Kappa opioid receptor localization and coupling to nitric oxide production in cells of the anterior chamber.

Authors:  Karen R Russell-Randall; Juanita Dortch-Carnes
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-13       Impact factor: 4.799

4.  1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.

Authors:  Galina D Kutuzova; B'ann T Gabelt; Julie A Kiland; Elizabeth A Hennes-Beann; Paul L Kaufman; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

5.  Intraocular pressure with rebound tonometry and effects of topical intraocular pressure reducing medications in guinea pigs.

Authors:  Yue Di; Xiu-Mei Luo; Tong Qiao; Na Lu
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

6.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

7.  RES-loaded pegylated CS NPs: for efficient ocular delivery.

Authors:  Saravanakumar Pandian; Vinoth Jeevanesan; Chandrasekar Ponnusamy; Subramanian Natesan
Journal:  IET Nanobiotechnol       Date:  2017-02       Impact factor: 1.847

Review 8.  The vital role for nitric oxide in intraocular pressure homeostasis.

Authors:  Ester Reina-Torres; Michael L De Ieso; Louis R Pasquale; Michael Madekurozwa; Joseph van Batenburg-Sherwood; Darryl R Overby; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2020-11-28       Impact factor: 21.198

Review 9.  Critical evaluation of latanoprostene bunod in the treatment of glaucoma.

Authors:  Giancarlo A Garcia; Philip Ngai; Sameh Mosaed; Ken Y Lin
Journal:  Clin Ophthalmol       Date:  2016-10-18

10.  Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits.

Authors:  Muhammad Irfan Kamaruddin; Momoko Nakamura-Shibasaki; Yu Mizuno; Yoshiaki Kiuchi
Journal:  Clin Ophthalmol       Date:  2017-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.